Stroke Journal

FEBRUARY 1, 2024

Introduction:Ovarian hyperstimulation syndrome (OHSS) is a well-known complication of ovarian stimulation used during assisted reproductive technology cycles. Stroke, Volume 55, Issue Suppl_1 , Page A134-A134, February 1, 2024. were included from each dataset.

Thrombosis 40

Thrombosis Inpatient Embolism Myocardial Infarction 40

GEMMS

APRIL 8, 2024

Established by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) , the MIPS Program is pivotal in determining Medicare payment adjustments for healthcare practices. What is MIPS? By assessing a composite performance score, eligible clinicians stand to receive payment bonuses and penalties or remain unaffected by adjustments.

Medicare 52

Medicare Innovation Medicaid Patient Care 52

Vector Remote

MARCH 9, 2023

Since it was announced as a Class 1A recommendation in 2015 by the Heart Rhythm Society, cardiac remote patient monitoring has become the standard of care for cardiac device patients. Cardiac implantable devices are sophisticated technology that provide both therapy and diagnostics for patients with irregular heart rhythms.

Heart Failure 52

Heart Failure Patient Care Heart Rhythm Hypertension 52

GEMMS

MARCH 7, 2024

EHR technology certified to the 2015 Cures Update must be in place by October 3, 2023. While small practices may be exempt , those reporting must be aware of the changes we’ll see in Promoting Interoperability for 2023. For reporting in 2024, 25% of total score applies to Promoting Interoperability.

Medicare 52

Medicare CMS Document Technology 52

Cardiomatics

MAY 24, 2022

Due to the interest of the health service in new technologies and the undeniable possibilities of AIPM, such studies are a great help for employees involved in the development, evaluation, and implementation of AIPM. Due to the dynamic development of the product, AI models are assessed on different test sets.

Article 52

Article Best Practices Document Technology 52

DAIC

APRIL 17, 2024

to develop the next generation technology for cardiopulmonary resuscitation, announced today that Mike Black will be advising the Company as its first Chief Strategy Officer. He went on to be Vice President of Global Customer Experience at ZOLL Medical , a leading strategic company in EMS that acquired ACSI in 2015.”

Cardiac Arrest 105

Cardiac Arrest Innovation Technology Outcomes 105

DAIC

SEPTEMBER 11, 2024

percent of the patients treated between 2005 and 2009 to 6.82% of the patients treated between 2015 and 2019. Digital technologies may reveal it is even more common than the current analysis indicates. About 2 million of these people had been diagnosed with A-Fib, and the numbers grew over time, rising from 4.49

Atrial Fibrillation 92

Atrial Fibrillation Quality of Life Myocardial Infarction Kidney Disease 92

DAIC

SEPTEMBER 11, 2024

percent of the patients treated between 2005 and 2009 to 6.82% of the patients treated between 2015 and 2019. Digital technologies may reveal it is even more common than the current analysis indicates. About 2 million of these people had been diagnosed with A-Fib, and the numbers grew over time, rising from 4.49

Atrial Fibrillation 52

Atrial Fibrillation Quality of Life Myocardial Infarction Kidney Disease 52

Journal of Cardiovascular Electrophysiology

FEBRUARY 7, 2024

Abstract Introduction Despite advancements in implantable cardioverter-defibrillator (ICD) technology, sudden cardiac death (SCD) remains a persistent public health concern. The study aims to assess whether mortality and VT/VF events decreased in patients who received ICDs during different time periods (2007–2010, 2011–2014, and 2015–2018).

Defibrillator 40

Defibrillator Sudden Cardiac Death Tachycardia Public Health 40

Heart 2023 Conference

MAY 3, 2022

released the Celt ACD 2d technology vascular closure group withinside the U.S. million human beings died of cardiovascular ailment in 2015, accounting for about 31% of worldwide deaths. VASCADE VCS is an extravascular bioabsorbable closure tool. In 2017, Vasorum Ltd. and 2014, AccessClure Inc. Of those deaths, about 7.four

Laboratory 52

Laboratory Technology Stroke Strokes 52

Dr. Malcolm Kendrick

OCTOBER 30, 2024

GlaxoSmithKline: $400K Liposcience: £50K HPS2-THRIVE trial of niacin/laropiprant (2005-2015) Merck: £53M plus drug supply HPS3/TIMI55-REVEAL trial of anacetrapib (2010-2022) Merck: £108M plus drug supply HPS 4/TIMI 65 – ORION-4 (2017-ongoing) Novartis Pharma AG Switzerland: £73.7M SEARCH trial of simvastatin dose (1997-2010) Merck: £22.7M

Cholesterol 145

Cholesterol Article Research Diet 145